teleo/teleo-codex
8
0
Fork 0
Code Issues 22 Pull requests 10 Projects Releases Packages Wiki Activity Actions 1

auto-fix: strip 4 broken wiki links

Browse source 
Pipeline auto-fixer: removed [[ ]] brackets from links
that don't resolve to existing claims in the knowledge base.
This commit is contained in:
Teleo Agents 2026-03-18 18:47:02 +00:00
parent 982ee5df0f
commit 202d68a159
4 changed files with 4 additions and 4 deletions
Show stats Download patch file Download diff file Expand all files Collapse all files

2
domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md
View file

@ -97,7 +97,7 @@ If GLP-1 + exercise produces durable weight maintenance (3.5 kg regain vs 8.7 kg
### Additional Evidence (challenge)
*Source: [[2025-06-01-value-in-health-comprehensive-semaglutide-medicare-economics]] | Added: 2026-03-18*
*Source: 2025-06-01-value-in-health-comprehensive-semaglutide-medicare-economics | Added: 2026-03-18*
Value in Health modeling study shows Medicare saves $715M over 10 years with comprehensive semaglutide access across all indications, challenging the universal inflationary framing. The distinction is payment structure: risk-bearing integrated payers can be net positive while fragmented systems remain inflationary. T2D savings ($892M) exceed obesity costs ($205M) when multi-indication benefits compound.

2
domains/health/glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md
View file

@ -56,7 +56,7 @@ Quantified lifetime savings per subject: $14,431 from avoided T2D, $2,074 from a
### Additional Evidence (confirm)
*Source: [[2025-06-01-value-in-health-comprehensive-semaglutide-medicare-economics]] | Added: 2026-03-18*
*Source: 2025-06-01-value-in-health-comprehensive-semaglutide-medicare-economics | Added: 2026-03-18*
Medicare modeling quantifies the compound value: 38,950 CV events avoided, 6,180 deaths prevented over 10 years. Per 100,000 subjects: 2,791 MIs, 3,000 revascularizations, 487 strokes, 115 CV deaths avoided. Savings per subject: $14,431 from avoided T2D, $2,074 from avoided CKD, $1,512 from avoided CV events. The multi-organ protection creates sufficient offset to produce net savings when a single payer captures all benefits.

2
domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md
View file

@ -79,7 +79,7 @@ WHO's conditional recommendation requiring behavioral therapy combination provid
### Additional Evidence (extend)
*Source: [[2026-03-01-glp1-lifestyle-modification-efficacy-combined-approach]] | Added: 2026-03-18*
*Source: 2026-03-01-glp1-lifestyle-modification-efficacy-combined-approach | Added: 2026-03-18*
Weight regain data shows that even among patients who complete treatment, GLP-1 alone produces 8.7 kg regain (vs 7.6 kg placebo) while GLP-1 + exercise produces only 3.5 kg regain. This means low persistence may be economically rational for patients if the medication alone doesn't create lasting value—the 15% two-year persistence rate may reflect patients discovering that medication without lifestyle change produces temporary results.

2
domains/health/lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence.md
View file

@ -39,7 +39,7 @@ The source does not provide granular income-stratified discontinuation rates, so
### Additional Evidence (confirm)
*Source: [[2025-11-06-trump-novo-lilly-glp1-price-deals-medicare]] | Added: 2026-03-16*
*Source: 2025-11-06-trump-novo-lilly-glp1-price-deals-medicare | Added: 2026-03-16*
The Trump Administration deal establishes a $50/month out-of-pocket maximum for Medicare beneficiaries, explicitly targeting affordability as a persistence barrier. The $245/month Medicare price (down from ~$1,350) combined with the OOP cap is designed to address the affordability-driven discontinuation pattern observed in lower-income populations.